KNSA
Kiniksa Pharmaceuticals Ltd.
$36.08
+$0.66(+1.86%)
62
Overall
35
Value
90
Tech
--
Quality
Market Cap
$2.62B
Volume
267.06K
52W Range
$17.82 - $37.34
Target Price
$43.00
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | $38.5M | $220.2M | $270.3M | $423.2M | ||
| Total Revenue | -- | -- | -- | $38.5M | $220.2M | $270.3M | $423.2M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | -- | $9.1M | $22.9M | $33.4M | $60.9M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | $29.4M | $197.3M | $236.9M | $362.3M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $108.2M | $170.0M | $157.4M | $185.2M | $187.5M | $205.5M | $279.6M | ||
| Research & Development | $86.6M | $135.0M | $112.0M | $99.3M | $65.5M | $76.1M | $111.6M | ||
| Research Expense | $86.6M | $135.0M | $112.0M | $99.3M | $65.5M | $76.1M | $111.6M | ||
| Selling, General & Administrative | $21.6M | $35.0M | $45.3M | $85.9M | $98.0M | $129.4M | $168.0M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $9.1M | $11.4M | ||
| General & Administrative Expenses | $21.6M | $35.0M | $45.3M | $85.9M | $98.0M | $129.4M | $168.0M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | $9.1M | $11.4M | ||
| Salaries & Wages | $-5.7M | -- | -- | -- | $25.1M | $27.1M | $30.7M | ||
| Depreciation & Amortization | $-286.0K | $2.1M | $2.4M | $1.5M | $1.2M | $1.1M | $448.0K | ||
| Depreciation & Amortization | $-286.0K | $2.1M | $2.4M | $1.5M | $1.2M | $1.1M | $448.0K | ||
| Amortization | -- | -- | -- | $1.0M | $1.0M | $1.0M | $1.0M | ||
| Other Operating Expenses | -- | $-528.0K | $-411.0K | $-50.0K | $-1.4M | $4.8M | $-11.8M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-108.2M | $-170.0M | $-157.4M | $-156.6M | $9.8M | $-25.2M | $-45.6M | ||
| EBITDA | $-104.6M | $-165.3M | $-155.0M | $-154.3M | $11.0M | $-14.3M | $-34.5M | ||
| NON-OPERATING ITEMS | |||||||||
| Intinc | $4.7M | $6.0M | $1.1M | $97.0K | -- | $8.2M | $9.0M | ||
| Net Non-Operating Interest Income/Expense | $4.7M | $6.0M | $1.1M | $97.0K | $-1.3M | $8.2M | $9.0M | ||
| Other Income/Expense | -- | -- | -- | $-97.0K | $1.3M | $-8.5M | $-9.5M | ||
| Other Special Charges | -- | -- | -- | $97.0K | $1.3M | $8.5M | $9.5M | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-103.4M | $-163.9M | $-157.4M | $-156.6M | $11.0M | $-16.7M | $-36.2M | ||
| Pre-Tax Income | $-103.4M | $-163.9M | $-156.2M | $-156.5M | $11.0M | $-16.7M | $-36.2M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-214.0K | $-2.0M | $5.2M | $1.4M | $-172.3M | $-30.7M | $7.0M | ||
| NET INCOME | |||||||||
| Net Income | $-103.2M | $-161.9M | $-161.4M | $-157.9M | $183.4M | $14.1M | $-43.2M | ||
| Net Income (Continuing Operations) | $-103.2M | $-161.9M | $-161.4M | $-157.9M | $183.4M | $14.1M | $-43.2M | ||
| Net Income (Discontinued Operations) | $-103.2M | $-161.9M | $-161.4M | $-157.9M | $183.4M | $14.1M | $-43.2M | ||
| Net Income (Common Stockholders) | $-103.2M | $-161.9M | $-161.4M | $-157.9M | $183.4M | $14.1M | $-43.2M | ||
| Normalized Income | -- | -- | -- | -- | $-161.3M | $-47.4M | $-35.8M | ||
| TOTALS | |||||||||
| Total Expenses | $108.2M | $170.0M | $157.4M | $194.3M | $210.4M | $238.9M | $340.5M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $29.5M | $54.0M | $61.8M | $68.6M | $69.4M | $70.1M | $71.4M | ||
| Average Shares Outstanding (Diluted) | $29.5M | $54.0M | -- | $68.6M | $70.4M | $71.9M | $71.4M | ||
| Shares Outstanding | $108.7M | $111.1M | $136.5M | $138.2M | $139.5M | $141.2M | $145.3M | ||
| Basic EPS | -- | $-2.99 | $-2.61 | $-2.3 | $2.64 | $0.20 | $-0.60 | ||
| Basic EPS (Continuing Operations) | -- | $-2.99 | $-2.61 | $-2.3 | $2.64 | $0.20 | $-0.60 | ||
| Diluted EPS | $-3.49 | $-2.99 | $-2.61 | $-2.3 | $2.6 | $0.20 | $-0.60 | ||
| Diluted EPS (Continuing Operations) | $-3.49 | -- | -- | $-2.3 | $2.6 | $0.20 | $-0.60 | ||
| OTHER METRICS | |||||||||
| Other Gand A | $21.6M | $35.0M | $45.3M | $85.9M | $98.0M | $129.4M | $168.0M | ||
| Rent And Landing Fees | $-935.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KNSA | $36.08 | +1.9% | 267.06K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kiniksa Pharmaceuticals Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW